Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Numéro 10, Octobre 2014
Page(s) 889 - 895
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20143010016
Publié en ligne 14 octobre 2014
  1. Hunt LT, Dayhoff MO. A surprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha 1-proteinase inhibitor. Biochem Biophys Res Commun 1980 ; 95 : 864–871. [CrossRef] [PubMed] [Google Scholar]
  2. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001 ; 276 : 33293–33296. [CrossRef] [PubMed] [Google Scholar]
  3. Cichy J, Potempa J, Travis J. Biosynthesis of alpha1-proteinase inhibitor by human lung-derived epithelial cells. J Biol Chem 1997 ; 272 : 8250–8255. [CrossRef] [PubMed] [Google Scholar]
  4. Venembre P, Boutten A, Seta N, et al. Secretion of alpha 1-antitrypsin by alveolar epithelial cells. FEBS Lett 1994 ; 346 : 171–174. [CrossRef] [PubMed] [Google Scholar]
  5. Paakko P, Kirby M, du Bois RM, et al. Activated neutrophils secrete stored alpha 1-antitrypsin. Am J Respir Crit Care Med 1996 ; 154 : 1829–1833. [CrossRef] [PubMed] [Google Scholar]
  6. Mornex JF, Chytil-Weir A, Martinet Y, et al. Expression of the alpha-1-antitrypsin gene in mononuclear phagocytes of normal and alpha-1-antitrypsin-deficient individuals. J Clin Invest 1986 ; 77 : 1952–1961. [CrossRef] [PubMed] [Google Scholar]
  7. Bouchecareilh M, Balch WE. Proteostasis, an emerging therapeutic paradigm for managing inflammatory airway stress disease. Curr Mol Med 2012 ; 12 : 815–826. [CrossRef] [PubMed] [Google Scholar]
  8. Baugh RJ, Travis J. Human leukocyte granule elastase: rapid isolation and characterization. Biochemistry 1976 ; 15 : 836–841. [CrossRef] [PubMed] [Google Scholar]
  9. Gooptu B, Ekeowa UI, Lomas DA. Mechanisms of emphysema in alpha1-antitrypsin deficiency: molecular and cellular insights. Eur Respir J 2009 ; 34 : 475–488. [CrossRef] [PubMed] [Google Scholar]
  10. Bouchecareilh M, Balch WE. Proteostasis: a new therapeutic paradigm for pulmonary disease. Proc Am Thorac Soc 2011 ; 8 : 189–195. [CrossRef] [PubMed] [Google Scholar]
  11. Stoller JK, Aboussouan LS. A review of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2012 ; 185 : 246–259. [CrossRef] [PubMed] [Google Scholar]
  12. Gooptu B, Dickens JA, Lomas DA. The molecular and cellular pathology of alpha1-antitrypsin deficiency. Trends Mol Med 2014 ; 20 : 116–127. [PubMed] [Google Scholar]
  13. Ghouse R, Chu A, Wang Y, Perlmutter DH. Mysteries of alpha1-antitrypsin deficiency: emerging therapeutic strategies for a challenging disease. Dis Model Mech 2014 ; 7 : 411–419. [CrossRef] [PubMed] [Google Scholar]
  14. Laurell CB, Eriksson S. The electrophoretic alpha-1-globulin pattern of serum in alpha-1-antitrypsin deficiency. Scand J Clin Lab Invest 1963 ; 15 : 132–140. [CrossRef] [Google Scholar]
  15. Sharp HL, Bridges RA, Krivit W, Freier EF. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med 1969 ; 73 : 934–939. [PubMed] [Google Scholar]
  16. Perlmutter DH. Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest 2002 ; 110 : 1579–1583. [CrossRef] [PubMed] [Google Scholar]
  17. Perlmutter DH. Alpha-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. Annu Rev Med 2011 ; 62 : 333–345. [CrossRef] [PubMed] [Google Scholar]
  18. Ogushi F, Fells GA, Hubbard RC, et al. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987 ; 80 : 1366–1374. [CrossRef] [PubMed] [Google Scholar]
  19. Bouchecareilh M, Hutt DM, Szajner P, et al. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of alpha1-antitrypsin deficiency. J Biol Chem 2012 ; 287 : 38265–38278. [CrossRef] [PubMed] [Google Scholar]
  20. Cameron PH, Chevet E, Pluquet O, et al. Calnexin phosphorylation attenuates the release of partially misfolded alpha1-antitrypsin to the secretory pathway. J Biol Chem 2009 ; 284 : 34570–34579. [CrossRef] [PubMed] [Google Scholar]
  21. Granell S, Baldini G, Mohammad S, et al. Sequestration of mutated alpha1-antitrypsin into inclusion bodies is a cell-protective mechanism to maintain endoplasmic reticulum function. Mol Biol Cell 2008 ; 19 : 572–586. [CrossRef] [PubMed] [Google Scholar]
  22. Qu D, Teckman JH, Omura S, Perlmutter DH. Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem 1996 ; 271 : 22791–22795. [CrossRef] [PubMed] [Google Scholar]
  23. Marcus NY, Perlmutter DH. Glucosidase and mannosidase inhibitors mediate increased secretion of mutant alpha1 antitrypsin Z. J Biol Chem 2000 ; 275 : 1987–1992. [CrossRef] [PubMed] [Google Scholar]
  24. Schmidt BZ, Perlmutter DH. Grp78, Grp94, and Grp170 interact with alpha1-antitrypsin mutants that are retained in the endoplasmic reticulum. Am J Physiol Gastrointest Liver Physiol 2005 ; 289 : G444–G455. [CrossRef] [PubMed] [Google Scholar]
  25. Papp E, Szaraz P, Korcsmaros T, Csermely P. Changes of endoplasmic reticulum chaperone complexes, redox state, and impaired protein disulfide reductase activity in misfolding alpha1-antitrypsin transgenic mice. FASEB J 2006 ; 20 : 1018–1020. [CrossRef] [PubMed] [Google Scholar]
  26. Nyfeler B, Reiterer V, Wendeler MW, et al. Identification of ERGIC-53 as an intracellular transport receptor of alpha1-antitrypsin. J Cell Biol 2008 ; 180 : 705–712. [CrossRef] [PubMed] [Google Scholar]
  27. Zhang B, Zheng C, Zhu M, et al. Mice deficient in LMAN1 exhibit FV and FVIII deficiencies and liver accumulation of alpha1-antitrypsin. Blood 2011 ; 118 : 3384–3391. [CrossRef] [PubMed] [Google Scholar]
  28. Crowther DC, Belorgey D, Miranda E, et al. Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies. Eur J Hum Genet 2004 ; 12 : 167–172. [CrossRef] [PubMed] [Google Scholar]
  29. Marciniak SJ, Lomas DA. Alpha1-antitrypsin deficiency and autophagy. N Engl J Med 2010 ; 363 : 1863–1864. [CrossRef] [PubMed] [Google Scholar]
  30. Piitulainen E, Carlson J, Ohlsson K, Sveger T. Alpha1-antitrypsin deficiency in 26-year-old subjects: lung, liver, and protease/protease inhibitor studies. Chest 2005 ; 128 : 2076–2081. [CrossRef] [PubMed] [Google Scholar]
  31. Pan S, Huang L, McPherson J, et al. Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha1-antitrypsin deficiency. Hepatology 2009 ; 50 : 275–281. [CrossRef] [PubMed] [Google Scholar]
  32. Hidvegi T, Ewing M, Hale P, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010 ; 329 : 229–232. [CrossRef] [PubMed] [Google Scholar]
  33. Gelling CL, Dawes IW, Perlmutter DH, et al. The endosomal protein-sorting receptor sortilin has a role in trafficking alpha-1 antitrypsin. Genetics 2012 ; 192 : 889–903. [CrossRef] [PubMed] [Google Scholar]
  34. Hidvegi T, Schmidt BZ, Hale P, Perlmutter DH. Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response. J Biol Chem 2005 ; 280 : 39002–39015. [CrossRef] [PubMed] [Google Scholar]
  35. Bouchecareilh M, Chevet E. Stress du réticulum endoplasmique : une réponse pour éviter le pIRE. Med Sci (Paris) 2009 ; 25 : 281–287. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  36. Smith SE, Granell S, Salcedo-Sicilia L, et al. Activating transcription factor 6 limits intracellular accumulation of mutant alpha1-antitrypsin Z and mitochondrial damage in hepatoma cells. J Biol Chem 2011 ; 286 : 41563–41577. [CrossRef] [PubMed] [Google Scholar]
  37. Carroll TP, Greene CM, O’Connor CA, et al. Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency. J Immunol 2010 ; 184 : 4538–4546. [CrossRef] [PubMed] [Google Scholar]
  38. Lawless MW, Greene CM, Mulgrew A, et al. Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol 2004 ; 172 : 5722–5726. [CrossRef] [PubMed] [Google Scholar]
  39. Miranda E, Perez J, Ekeowa UI, et al. A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with alpha1-antitrypsin deficiency. Hepatology 2010 ; 52 : 1078–1088. [CrossRef] [PubMed] [Google Scholar]
  40. Mahadeva R, Atkinson C, Li Z, et al. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005 ; 166 : 377–386. [CrossRef] [PubMed] [Google Scholar]
  41. Alam S, Li Z, Janciauskiene S, Mahadeva R. Oxidation of Z alpha1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. Am J Respir Cell Mol Biol 2011 ; 45 : 261–269. [CrossRef] [PubMed] [Google Scholar]
  42. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci USA 2000 ; 97 : 1796–1801. [CrossRef] [Google Scholar]
  43. Mendre C, Mouillac B. Chaperons pharmacologiques : un espoir thérapeutique pour les pathologies conformationnelles. Med Sci (Paris) 2010 ; 26 : 627–635. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  44. Kelly WK, O’Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005 ; 23 : 3923–3931. [CrossRef] [PubMed] [Google Scholar]
  45. Choi SM, Kim Y, Shim JS, et al. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology 2013 ; 57 : 2458–2468. [CrossRef] [PubMed] [Google Scholar]
  46. Li J, Pak SC, O’Reilly LP, et al. Fluphenazine reduces proteotoxicity in C. elegans, mammalian models of alpha-1-antitrypsin deficiency. PLoS One 2014 ; 9 : e87260. [CrossRef] [PubMed] [Google Scholar]
  47. Flotte TR, Mueller C. Gene therapy for alpha-1 antitrypsin deficiency. Hum Mol Genet 2011 ; 20 : R87–R92. [CrossRef] [PubMed] [Google Scholar]
  48. Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011 ; 478 : 391–394. [CrossRef] [PubMed] [Google Scholar]
  49. Guo S, Booten SL, Aghajan M, et al. Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice. J Clin Invest 2014 ; 124 : 251–261. [CrossRef] [PubMed] [Google Scholar]
  50. Alam S, Wang J, Janciauskiene S, Mahadeva R. Preventing and reversing the cellular consequences of Z alpha-1 antitrypsin accumulation by targeting s4A. J Hepatol 2012 ; 57 : 116–124. [CrossRef] [PubMed] [Google Scholar]
  51. Ekeowa UI, Freeke J, Miranda E, et al. Defining the mechanism of polymerization in the serpinopathies. Proc Natl Acad Sci USA 2010 ; 107 : 17146–17151. [CrossRef] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.